Tweet
Influenza Other Respir Viruses
. 2024 Dec;18(12):e70025.
doi: 10.1111/irv.70025. Comparative Effectiveness of Cell-Based Versus Egg-Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022-2023 Season Among Adults 18-64 Years
Emily Rayens 1 , Jennifer H Ku 1 , Lina S Sy 1 , Lei Qian 1 , Bradley K Ackerson 1 , Yi Luo 1 , Julia E Tubert 1 , Gina S Lee 1 , Punam P Modha 1 , Yoonyoung Park 2 , Tianyu Sun 3 , Evan J Anderson 2 , **** Fu Tseng 1 4
Affiliations
This retrospective cohort study evaluated the comparative vaccine effectiveness (cVE) of licensed standard-dose cell-based versus egg-based influenza vaccines in preventing influenza hospitalization among adults 18-64 years during the 2022-2023 season. The cohort included eligible Kaiser Permanente Southern California members who received ≥ 1 dose of influenza vaccine (n = 848,334). The adjusted cVE against influenza hospitalization was -10.1% (95% CI: -49.8%, 37.8%) in the 18- to 49-year-old cohort. In the 50- to 64-year-old cohort, the adjusted cVE was 14.9% (-33.8%, 52.1%). Cell-based and egg-based influenza vaccines conferred comparable protection against influenza hospitalization in adults 18-64 years of age in the 2022-2023 season.
Keywords: Influenza; epidemiology; influenza vaccine; vaccine effectiveness.
. 2024 Dec;18(12):e70025.
doi: 10.1111/irv.70025. Comparative Effectiveness of Cell-Based Versus Egg-Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022-2023 Season Among Adults 18-64 Years
Emily Rayens 1 , Jennifer H Ku 1 , Lina S Sy 1 , Lei Qian 1 , Bradley K Ackerson 1 , Yi Luo 1 , Julia E Tubert 1 , Gina S Lee 1 , Punam P Modha 1 , Yoonyoung Park 2 , Tianyu Sun 3 , Evan J Anderson 2 , **** Fu Tseng 1 4
Affiliations
- PMID: 39696975
- PMCID: PMC11655916
- DOI: 10.1111/irv.70025
This retrospective cohort study evaluated the comparative vaccine effectiveness (cVE) of licensed standard-dose cell-based versus egg-based influenza vaccines in preventing influenza hospitalization among adults 18-64 years during the 2022-2023 season. The cohort included eligible Kaiser Permanente Southern California members who received ≥ 1 dose of influenza vaccine (n = 848,334). The adjusted cVE against influenza hospitalization was -10.1% (95% CI: -49.8%, 37.8%) in the 18- to 49-year-old cohort. In the 50- to 64-year-old cohort, the adjusted cVE was 14.9% (-33.8%, 52.1%). Cell-based and egg-based influenza vaccines conferred comparable protection against influenza hospitalization in adults 18-64 years of age in the 2022-2023 season.
Keywords: Influenza; epidemiology; influenza vaccine; vaccine effectiveness.